Alopecia areata is the second most common non-scarring alopecia and there are no clear reasons for the onset of the condition

LONDON, May 19, 2022 (GLOBE NEWSWIRE) -- Some sources have suggested that alopecia areata (AA) happens due to genetic susceptibility and environmental change. While there are off-label treatments used to manage AA, including systemic and localized therapies, there are no FDA-approved treatments for the condition. The most common treatment option is corticosteroid use, either administered as an injection intradermally (injected with intralesional corticosteroid triamcinolone), or applied topically as a cream, ointment, or gel.

The Alopecia Areata Marketed and Pipeline Drugs Assessment Report offered by GlobalData Plc looks at the data-driven overview of the current and future competitive landscape in alopecia areata therapeutics. This report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, late-to-mid-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for alopecia areata (AA). The report also analyzes the clinical and commercial landscapes of AA, as well as an assessment of deals, future market catalysts, key market players, and the future competitive environment.

Key Findings

In 2022, GlobalData estimates that the highest prevalent cases of AA will be in India and China, representing almost 40% and 35% of global cases, respectively. There are no approved therapies for AA and so limited treatment guidelines are available. Only recommendations related to conventional and off-label therapies are available for physicians for the management of AA. R&D activities have focused on developing targeted therapies such as JAK inhibitors due to the increased knowledge of the pathophysiology of AA and the contribution of autoimmunity to the loss of hair.

For more key findings on alopecia areata marketed and pipeline drugs, download a free report sample

Alopecia Areata Drugs Market Segmentation by Mechanism of Action

• Receptor Agonist

• Receptor Antagonist

• Enzyme Inhibitor

• Protein & Peptide Inhibitor

• Biological Factor Inhibitor
  
  

Alopecia Areata Drugs Market Analysis by Mechanism of Action

For more mechanism of action insights, download a free report sample

Alopecia Areata Drugs Market Segmentation by Routes of Administration

• Oral Therapies

• Injections

• Topical Therapies
  
  

Alopecia Areata Drugs Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

Alopecia Areata Marketed and Pipeline Drugs Market Overview

Alopecia Areata Marketed and Pipeline Drugs Market Report Scope

GlobalData’s Alopecia Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape, 2022 Update combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include:

• Disease Landscape

• Disease Overview

• Epidemiology Overview

• Treatment Overview

• Marketed Products Assessment

• Breakdown by Mechanism of Action, Molecule Type, and Route of Administration

• Product Profiles with Sales Forecast

• Pipeline Assessment

• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration

• Late-to-mid-stage Pipeline Drugs

• Phase Transition Success Rate and Likelihood of Approval

• Clinical Trials Assessment

• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status

• Enrolment Analytics, Site Analytics, Feasibility Analysis

• Deals Landscape

• Mergers, Acquisitions, and Strategic Alliances by Region

• Overview of Recent Deals

• Commercial Assessment

• Key Market Players

• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

• Develop business strategies by understanding the trends shaping and driving the alopecia market.

• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global alopecia market in the future.

• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

• Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.

• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

FAQs

What are the major mechanisms of action in the alopecia areata pipeline drugs market?

The major mechanisms of action in the alopecia areata pipeline drugs market are receptor agonist, receptor antagonist, enzyme inhibitor, protein & peptide inhibitor, and biological factor inhibitor.

What are the major routes of administration in the alopecia areata pipeline drugs market?

The major routes of administration in the alopecia areata pipeline drugs market are oral therapies, injections, and topical therapies.

Related Reports

• Androgenic Alopecia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players – Click here

• Alopecia – Global Clinical Trials Review, 2022 – Click here

• Acquired (Autoimmune) Hemolytic Anemia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players – Click here

• Renal Cell Carcinoma Marketed and Pipeline Drugs Assessment, Clinical Trials, Social Media and Competitive Landscape – Click here

• Acute Coronary Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players – Click here
  
  

About us

GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.

Media Contacts

GlobalData

Mark Jephcott
Head of PR EMEA
mark.jephcott@globaldata.com
cc: pr@globaldata.com

+44 (0)207 936 6400